从混合性结缔组织病谱系解读IPAF、VEDOSS与结缔组织病分类
诊断时满足IPAF或VEDOSS标准均不能预测向SSc进展,而抗磷脂抗体和低补体C3和/或C4可预测向SLE进展。
要点
- MCTD诊断时满足IPAF标准者进展为dCTD的比例与不满足者无显著差异(p=0.09)。
- MCTD诊断时满足VEDOSS标准者进展为SSc的比例与不满足者无显著差异(p=0.8)。
- 抗磷脂抗体和低C3和/或C4可预测MCTD向SLE进展。
核心结论
- MCTD诊断时满足IPAF和/或VEDOSS标准不能预测向SSc进展,而抗磷脂抗体和低C3和/或C4可预测向SLE进展。
- 原文提示MCTD患者应被排除在IPAF和VEDOSS之外。
研究设计与样本
- 使用IPAF、VEDOSS及当前dCTD分类标准对患者进行分类。
主要发现
- 诊断时38例(11.7%)满足IPAF标准,其中15例(39.5%)进展为dCTD,而不满足IPAF标准者中75例(26.2%)进展为dCTD(p=0.09)。
- 诊断时293例(90.4%)满足VEDOSS标准,其向SSc进展的比例与不满足VEDOSS标准者无显著差异(46例(15.7%) vs 4例(12.9%);p=0.8)。
- 基线时SSc分类标准未预测向SSc evolution,而抗磷脂抗体和低C3和/或C4分别预测向SLE evolution(p=0.01和p=0.04)。
关键数值与推荐
- 抗磷脂抗体预测向SLE evolution的p=0.01;低C3和/或C4预测向SLE evolution的p=0.04。
临床怎么用
- 在MCTD诊断时,IPAF和VEDOSS标准的满足情况未显示可预测向SSc进展。
- 抗磷脂抗体和低C3和/或C4可预测MCTD向SLE进展。
- 原文建议MCTD患者应被排除在IPAF和VEDOSS之外。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of differentiated connective tissue diseases (dCTD), similarly to interstitial pneumonia with autoimmune features (IPAF) and very early diagnosis of systemic sclerosis (SSc) (VEDOSS). OBJECTIVE: We aimed to evaluate the predictive value of IPAF, VEDOSS and dCTD classification criteria variables in MCTD patients. METHODS: We conducted an observational study within the French MCTD cohort. IPAF, VEDOSS and current dCTD classification criteria were used to classify patients. RESULTS: Three hundred and twenty-four MCTD patients were included and followed for 8 (3.3-13) years. Among them, 111 (34.3%) progressed into a dCTD, that is, 50 (15.4%) SSc, 40 (12.3%) systemic lupus erythematosus (SLE) and 11 (3.4%) Sjögren's disease. At diagnosis, 38 (11.7%) patients fulfilled IPAF criteria, among which 15 (39.5%) progressed into a dCTD (vs 75 (26.2%) in patients who did not fulfil IPAF criteria; p=0.09). At diagnosis, 293 (90.4%) patients fulfilled VEDOSS criteria but did not progress significantly more frequently to SSc than MCTD patients without VEDOSS criteria (46 (15.7%) vs 4 (12.9%); p=0.8). At baseline, SSc classification criteria did not predict evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE (p=0.01 and p=0.04, respectively). CONCLUSION: At MCTD diagnosis, fulfilment of IPAF and/or VEDOSS criteria was not predictive of evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE. This suggests that MCTD patients should be excluded from IPAF and VEDOSS.
引用
- Chevalier K, Thoreau B, Michel M, et al. Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum. RMD Open. 2025. PMID: 41130746. doi:10.1136/rmdopen-2025-006145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。